11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

      Lancet
      Animals, Animals, Genetically Modified, Cardiomyopathy, Hypertrophic, complications, drug therapy, Glycogen Storage Disease Type II, Humans, Milk, chemistry, Rabbits, Recombinant Proteins, isolation & purification, therapeutic use, alpha-Glucosidases

      Read this article at

      ScienceOpenPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pompe's disease is a fatal muscular disorder caused by lysosomal alpha-glucosidase deficiency. In an open-label study, four babies with characteristic cardiomyopathy were treated with recombinant human alpha-glucosidase (rhGAA) from rabbit milk at starting doses of 15 mg/kg or 20 mg/kg, and later 40 mg/kg. The enzyme was generally well tolerated. Activity of alpha-glucosidase normalised in muscle. Tissue morphology and motor and cardiac function improved. The left-ventricular-mass index decreased significantly. We recommend early treatment. Long-term effects are being studied.

          Related collections

          Author and article information

          Comments

          Comment on this article